Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3467-3474

  Darlix, Amelie ^a,f   Baumann, Cedric ^a   Lorgis, Veronique ^b,f   Ghiringhelli, Francois ^b,f   Blonski, Marie ^a,f   Chauffert, Bruno ^c,f   Zouaoui, Sonia ^d,e   Pinelli, Catherine ^a,f   Rech, Fabien ^a,f   Beauchesne, Patrick ^a,f   Taillandier, Luc ^a,f  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Georges Francois Leclerc Cancer Center   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d CENTRE VAL D AURELLE   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f NENO Groupe de Neurooncologie du Nord Est   (France)

Author keywords

Glioblastoma; Prolonged adjuvant therapy; Radiochemotherapy; Temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN BIOPSY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HISTOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA; LEUKOPENIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TUMOR RECURRENCE;

GLIOBLASTOMA; PROLONGED ADJUVANT THERAPY; RADIOCHEMOTHERAPY; TEMOZOLOMIDE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883266533     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY: Primary brain tumours in adults. Lancet 379: 1984-1996, 2012.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Stupp R, Hegi ME, Mason WP, van den Bent M, Taphoorn MJB, Janzer RC, Ludwin, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek, Marosi K, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
4. Holdhoff M, Grossman SA: Controversies in the Adjuvant Therapy of High-Grade Gliomas. Oncologist 16: 351-358, 2011.
5. Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, Rauch M, Brenner A, Rieckmann P, Schuth J, Jauch T, Koch and Bogdahn U: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68: 688-690, 2007.
6. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, Wenz F, Thome C and Tuettenberg: Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: Experience of a single institution. J Cancer Res Clin Oncol 136: 1691-1695, 2010.
7. Roldan Urgoiti GB, Singh AD and Easaw JC: Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol 108: 173-177, 2012.
8. Mason WP, Del Maestro R, Eisenstat D, Forsyth P, Fulton D, Laperriere N, Macdonald D, Perry J and Thiessen B: Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 14: 110-117, 2007.
9. Gerber DE, Grossman SA, Zeltzman M, Parisi MA and Kleinberg L: The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9: 47-52, 2007.
10. Khasraw M, Bell D, Wheeler H: Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? J Clin Neurosci 16: 854-855, 2009.
11. Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, Thorin J, Pacaut C, Peoc'h M, Nuti C, Schmitt and Magne N: Prolonged temozolomide for treatment of glioblastoma: Preliminary clinical result and prognostic value of p53 overexpression. J Neurooncol 106: 127-133, 2012.
12. Macdonald DR, Cascino TL, Schold SC Jr. and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
13. Delion M, Moraru C, Almayrac F, Von Langsdorff D, Paquis P and Menei P: Glioblastoma incident studies from May 2006 to May 2007 in Angers and Nice, France. Neurochirurgie 56: 499-502, 2010.
14. Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, Kim ST, Lim DH, Kim WS and Nam DH: Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: Single-center experience. Clin Neurol Neurosurg 111: 679-682, 2009.
15. van Genugten JAB, Leffers P, Baumert BG, Tjon-a-Fat H and Twijnstra A: Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol 96: 249-257, 2010.
16. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD and Friedman HS: The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17: 4119-4124, 2011.
17. Villano JL, Letarte N, Yu JM, Abdur S and Bressler L: Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol 69: 107-113, 2012.
18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Engl J Med 352: 997-1003, 2005.